Free Trial
NASDAQ:NRBO

NeuroBo Pharmaceuticals 5/9/2024 Earnings Report

NeuroBo Pharmaceuticals logo
$0.60 -0.01 (-2.07%)
As of 08/4/2025

NeuroBo Pharmaceuticals EPS Results

Actual EPS
-$1.32
Consensus EPS
-$0.95
Beat/Miss
Missed by -$0.37
One Year Ago EPS
N/A

NeuroBo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NeuroBo Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

NeuroBo Pharmaceuticals' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

NeuroBo Pharmaceuticals Earnings Headlines

Market Crash Warning: How to Protect Your Wealth Before August 12th
New China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shifting out of stocks, while everyday investors remain exposed. A free guide reveals where the smart money is going—and how to protect your wealth before the next sell-off.
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes
NeuroBo Pharmaceuticals announces relignment, change name
See More NeuroBo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeuroBo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroBo Pharmaceuticals and other key companies, straight to your email.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals (NASDAQ:NRBO), a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

View NeuroBo Pharmaceuticals Profile

More Earnings Resources from MarketBeat